Pear Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christopher D. T. Guiffre MBA
- Full Time Employees
- 200
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- 200 State Street Boston MA United States of America 02109
- IPO Date
- Mar 31, 2021
- CIK
- 0001835567
- Website
- peartherapeutics.com
- Similar Companies
- Business
- Pear Therapeutics, Inc. Pear Therapeutics, Inc. (PEAR) develops and commercializes prescription digital therapeutics, software-based medicines designed to treat diseases such as substance use disorder, opioid use disorder, and chronic insomnia through clinically validated mobile applications that deliver cognitive behavioral therapy, contingency management, and clinician dashboards. The company's primary products include reSET, an FDA-cleared adjunctive therapy for substance use disorder in patients 18 years and older; reSET-O, indicated for opioid use disorder in combination with buprenorphine; and Somryst, for chronic insomnia; with a pipeline historically encompassing candidates for schizophrenia, post-traumatic stress disorder, anxiety, pain, and depression. Founded in 2013 and headquartered in Boston, Massachusetts, Pear Therapeutics operates in the United States, targeting patients, clinicians, and payers in behavioral health and neurology segments via its PearConnect platform. In April 2023, the company filed for Chapter 11 bankruptcy, laid off approximately 92% of its workforce, and initiated a sale process; its key digital therapeutic assets, including reSET and reSET-O, were subsequently acquired in December 2023 by PursueCare, a digital addiction treatment provider that raised $20 million in Series B funding to integrate and relaunch the products within its value-based care model focused on Medicaid-managed arrangements and health system partnerships across 11 states.
P&G'S THE NATIVE BRAND LAUNCHES FEATURE-LENGTH "MICROSOAP" TITLED "THE GOLDEN PEAR AFFAIR" AVAILABLE ONLINE NOW, MARKING A NEW CHAPTER IN P&G'S LEGACY OF SOAP STORYTELLING
Why Is Pear Therapeutics (PEAR) Stock Down 26% Today?
Why Is Pear Therapeutics (PEAR) Stock Up 21% Today?
Pear Therapeutics, Inc. (PEAR) Loses -17.39% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Pear Has Captive Markets With reSET, Guides $30 Million In 2023
Pear Therapeutics Inc. (PEAR) Q3 2022 Earnings Call Transcript
Pear Therapeutics Reports Third Quarter 2022 Results
Pear Therapeutics Lays Off 9% Of Workforce, Guides For $15 Million Revenue
Pear Therapeutics, Inc. (PEAR) CEO Corey McCann on Q2 2022 Results - Earnings Call Transcript
Why Earnings Season Could Be Great for Pear Therapeutics (PEAR)
Penny Stocks To Buy Now? 3 With Unusual Options Activity To Watch
Pear Therapeutics Sees Growing Fulfillment Rates And Payor Traction
Pear Therapeutics, Inc. (PEAR) CEO Corey McCann on Q1 2022 Results - Earnings Call Transcript
Pear Therapeutics Reports First Quarter 2022 Financial Results
Pear Therapeutics to Present at 2022 Rx and Illicit Drug Summit
Pear Therapeutics Guiding For Being 1% Down The Potential Runway In Current Markets
Pear Therapeutics, Inc. (PEAR) CEO Corey McCann on Q4 2021 Results - Earnings Call Transcript
Pear Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
Pear Therapeutics' Digital Therapeutic For Insomnia Shows Meaningful Reductions In Severity Through 6 Months
Even With Low Penetration Assumptions For PDTs, Pear Therapeutics Is A Buy